Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial

S. Peters, E. Felip, U. Dafni, C. Belka, M. Guckenberger, A. Irigoyen, E. Nadal, A. Becker, H. Vees, M. Pless, A. Martinez-Marti, A. Tufman, M. Lambrecht, N. Andratschke, A. C. Piguet, M. Kassapian, H. Roschitzki-Voser, M. Rabaglio-Poretti, R. A. Stahel, J. VansteenkisteD. De Ruysscher*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)83-87
Number of pages5
JournalLung Cancer
Volume133
DOIs
Publication statusPublished - Jul 2019

Keywords

  • Non-small cell lung cancer
  • NSCLC
  • Chemotherapy
  • Radiotherapy
  • Cancer immunotherapy
  • Immune checkpoint inhibitors
  • PD-1 inhibitor
  • Nivolumab
  • Combination treatment

Cite this

Peters, S., Felip, E., Dafni, U., Belka, C., Guckenberger, M., Irigoyen, A., Nadal, E., Becker, A., Vees, H., Pless, M., Martinez-Marti, A., Tufman, A., Lambrecht, M., Andratschke, N., Piguet, A. C., Kassapian, M., Roschitzki-Voser, H., Rabaglio-Poretti, M., Stahel, R. A., ... De Ruysscher, D. (2019). Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung Cancer, 133, 83-87. https://doi.org/10.1016/j.lungcan.2019.05.001